BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16010360)

  • 1. New pyrazolo[3,4-b]pyridones as selective A(1) adenosine receptor antagonists: synthesis, biological evaluation and molecular modelling studies.
    Fossa P; Pestarino M; Menozzi G; Mosti L; Schenone S; Ranise A; Bondavalli F; Trincavelli ML; Lucacchini A; Martini C
    Org Biomol Chem; 2005 Jun; 3(12):2262-70. PubMed ID: 16010360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent and selective inhibitors of A1 adenosine receptors.
    Manetti F; Schenone S; Bondavalli F; Brullo C; Bruno O; Ranise A; Mosti L; Menozzi G; Fossa P; Trincavelli ML; Martini C; Martinelli A; Tintori C; Botta M
    J Med Chem; 2005 Nov; 48(23):7172-85. PubMed ID: 16279775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.
    Tuccinardi T; Schenone S; Bondavalli F; Brullo C; Bruno O; Mosti L; Zizzari AT; Tintori C; Manetti F; Ciampi O; Trincavelli ML; Martini C; Martinelli A; Botta M
    ChemMedChem; 2008 Jun; 3(6):898-913. PubMed ID: 18338422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
    Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
    J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial profile against drug-resistant Staphylococcus epidermidis clinical strain and structure-activity relationship studies of 1H-pyrazolo[3,4-b]pyridine and thieno[2,3-b]pyridine derivatives.
    Leal B; Afonso IF; Rodrigues CR; Abreu PA; Garrett R; Pinheiro LC; Azevedo AR; Borges JC; Vegi PF; Santos CC; da Silveira FC; Cabral LM; Frugulhetti IC; Bernardino AM; Santos DO; Castro HC
    Bioorg Med Chem; 2008 Sep; 16(17):8196-204. PubMed ID: 18701299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antileishmanial pyrazolopyridine derivatives: synthesis and structure-activity relationship analysis.
    de Mello H; Echevarria A; Bernardino AM; Canto-Cavalheiro M; Leon LL
    J Med Chem; 2004 Oct; 47(22):5427-32. PubMed ID: 15481980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A₂B adenosine receptor antagonists.
    Baraldi PG; Baraldi S; Saponaro G; Preti D; Romagnoli R; Piccagli L; Cavalli A; Recanatini M; Moorman AR; Zaid AN; Varani K; Borea PA; Tabrizi MA
    J Med Chem; 2012 Jan; 55(2):797-811. PubMed ID: 22148859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
    J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the combination of optimal substitutions at the C²-, N⁵- and N⁸-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A₃ adenosine receptors?
    Cheong SL; Dolzhenko AV; Paoletta S; Lee EP; Kachler S; Federico S; Klotz KN; Dolzhenko AV; Spalluto G; Moro S; Pastorin G
    Bioorg Med Chem; 2011 Oct; 19(20):6120-34. PubMed ID: 21908194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists.
    Elzein E; Kalla R; Li X; Perry T; Parkhill E; Palle V; Varkhedkar V; Gimbel A; Zeng D; Lustig D; Leung K; Zablocki J
    Bioorg Med Chem Lett; 2006 Jan; 16(2):302-6. PubMed ID: 16275090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
    J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
    Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
    J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: potent and selective adenosine A1 receptor antagonists.
    Poulsen SA; Quinn RJ
    J Med Chem; 1996 Oct; 39(21):4156-61. PubMed ID: 8863792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
    Tabrizi MA; Baraldi PG; Preti D; Romagnoli R; Saponaro G; Baraldi S; Moorman AR; Zaid AN; Varani K; Borea PA
    Bioorg Med Chem; 2008 Mar; 16(5):2419-30. PubMed ID: 18077171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2'-furyl)-1,2,4-triazolo[1,5-a]quinoxalines.
    Martínez A; Gutiérrez-de-Terán H; Brea J; Raviña E; Loza MI; Cadavid MI; Sanz F; Vidal B; Segarra V; Sotelo E
    Bioorg Med Chem; 2008 Feb; 16(4):2103-13. PubMed ID: 18249548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological data of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters, a new series of A1-adenosine receptor (A1AR) ligands.
    Schenone S; Bruno O; Fossa P; Ranise A; Menozzi G; Mosti L; Bondavalli F; Martini C; Trincavelli L
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2529-31. PubMed ID: 11549462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Substituted pyrazolo[1,5-c]quinazolines as novel Gly/NMDA receptor antagonists: synthesis, biological evaluation, and molecular modeling study.
    Varano F; Catarzi D; Colotta V; Calabri FR; Lenzi O; Filacchioni G; Galli A; Costagli C; Deflorian F; Moro S
    Bioorg Med Chem; 2005 Oct; 13(19):5536-49. PubMed ID: 16087341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for new antagonist ligands for adenosine receptors from QSAR point of view. How close are we?
    González MP; Terán C; Teijeira M
    Med Res Rev; 2008 May; 28(3):329-71. PubMed ID: 17668454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.